Literature DB >> 1683057

Expression of MHC class II antigens in human lung cancer cells.

H Kamma1, T Yazawa, T Ogata, H Horiguchi, T Iijima.   

Abstract

Surgical specimens of lung cancers were examined immunopathologically for the expression of major histocompatibility complex class II (MHC-II) antigens in the tumor cells and their relationship to the lymphocytic infiltration. A lymphocytic infiltrate was frequently observed in the tumor tissue, though its intensity differed among the various histological types. MHC-II antigens were often demonstrated in tumors with a lymphocytic infiltrate. They were detected predominantly in the cytoplasm of tumor cells and to a lesser extent on the cell membranes. The emergence of the MHC-II-positive tumor cells was closely related to a local infiltration by lymphocytes including interferon-gamma (IFN-gamma)-producing T-cells. On the basis of the histological findings, an in vitro experiment was carried out. Four types of lung cancer cells were incubated with recombinant IFN-gamma in order to induce MHC-II antigens. MHC-II antigens (HLA-DR as well as HLA-DQ and HLA-DP antigens) were elicited in three cancer cell lines depending on the concentration of IFN-gamma. Immunoelectron microscopic study revealed that they were expressed on the surface of the cell membrane, though to a lesser extent than in the cytoplasm. It was considered that MHC-II antigens could be induced in some tumor cells in the immunological environment where IFN-gamma was secreted from T-cells and concentrated locally.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683057     DOI: 10.1007/bf02899573

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  14 in total

1.  Chemical and genetic control of IFNγ-induced MHCII expression.

Authors:  Ruud H Wijdeven; Marvin M van Luijn; Annet F Wierenga-Wolf; Jimmy J Akkermans; Peter J van den Elsen; Rogier Q Hintzen; Jacques Neefjes
Journal:  EMBO Rep       Date:  2018-07-18       Impact factor: 8.807

2.  Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.

Authors:  K V Woan; M Lienlaf; P Perez-Villaroel; C Lee; F Cheng; T Knox; D M Woods; K Barrios; J Powers; E Sahakian; H W Wang; J Canales; D Marante; K S M Smalley; J Bergman; E Seto; A Kozikowski; J Pinilla-Ibarz; A Sarnaik; E Celis; J Weber; E M Sotomayor; A Villagra
Journal:  Mol Oncol       Date:  2015-04-24       Impact factor: 6.603

3.  Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.

Authors:  Zoltan Lohinai; Balazs Dome; David Dora; Christopher Rivard; Hui Yu; Shivaun Lueke Pickard; Viktoria Laszlo; Tunde Harko; Zsolt Megyesfalvi; Csongor Gerdan; Elek Dinya; Konrad Hoetzenecker; Fred R Hirsch
Journal:  Cancer Immunol Immunother       Date:  2022-08-17       Impact factor: 6.630

4.  Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer.

Authors:  Denise Lau; Sonal Khare; Michelle M Stein; Prerna Jain; Yinjie Gao; Aicha BenTaieb; Tim A Rand; Ameen A Salahudeen; Aly A Khan
Journal:  Nat Commun       Date:  2022-07-13       Impact factor: 17.694

5.  Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma.

Authors:  Takuya Yazawa; Takaaki Ito; Hiroshi Kamma; Takehisa Suzuki; Koji Okudela; Hiroyuki Hayashi; Hisashi Horiguchi; Takesaburo Ogata; Hideaki Mitsui; Masaichi Ikeda; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

6.  Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma.

Authors:  Amber M Johnson; Bonnie L Bullock; Alexander J Neuwelt; Joanna M Poczobutt; Rachael E Kaspar; Howard Y Li; Jeff W Kwak; Katharina Hopp; Mary C M Weiser-Evans; Lynn E Heasley; Erin L Schenk; Eric T Clambey; Raphael A Nemenoff
Journal:  J Immunol       Date:  2020-03-16       Impact factor: 5.422

7.  A rare mediastinal tumour presenting with systemic effects due to IL-6 and tumour necrosis factor (TNF) production.

Authors:  K A Davies; A P Cope; J B Schofield; C Q Chu; J C Mason; T Krausz; P Smith; A M Denman; M J Walport
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

8.  Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer.

Authors:  Ila J Datar; Sacha C Hauc; Shruti Desai; Nicole Gianino; Brian Henick; Yuting Liu; Kostas Syrigos; David L Rimm; Paula Kavathas; Soldano Ferrone; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2021-02-18       Impact factor: 13.801

9.  Prognostic significance of major histocompatibility complex class II antigens (HLA-DR) in normal colonic mucosa, tubulovillous adenoma, and invasive colonic carcinoma.

Authors:  Demetrio Tamiolakis; Sylvia Nicolaidou; Sophia Bolioti; Anna Tzilivaki
Journal:  Ann Saudi Med       Date:  2006 Mar-Apr       Impact factor: 1.526

Review 10.  Lymphocyte-activation gene-3, an important immune checkpoint in cancer.

Authors:  Yayi He; Christopher J Rivard; Leslie Rozeboom; Hui Yu; Kim Ellison; Ashley Kowalewski; Caicun Zhou; Fred R Hirsch
Journal:  Cancer Sci       Date:  2016-08-25       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.